Supernus Pharmaceuticals Inc

Most Recent

  • is supernus pharma supn stock a buy
    Financials

    Supernus Stock Shows Promise in the ADHD Drug Market

    By Ruchi Gupta
  • uploads///Supernus
    Company & Industry Overviews

    A Financial Overview of Supernus Pharmaceuticals in September

    In Q2 2018, Supernus Pharmaceuticals (SUPN) reported net revenues of $99.5 million compared to $75.8 million in Q2 2017.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Supernus Pharmaceuticals Garners 89% ‘Buy’ Ratings in September

    Of the nine analysts tracking Supernus Pharmaceuticals (SUPN), three recommended a “strong buy” while five analysts recommended a “buy.”

    By Daniel Collins
  • uploads///BEAT PE MC
    Healthcare

    Analyzing BEAT, SUPN, ADBE And RHT Stocks

    Growth stock analysis   BioTelemetry BioTelemetry’s (BEAT) net income has declined at a 3-year and 5-year average of 17% and 5.9% respectively. The company’s negative pre-tax margin changed from 5.5% in 2013 to 3.6% in 2017. The stock prices have beaten the diagnostics & research industry and S&P 500 between 2013 and 2017. The market […]

    By Amanda Lawrence
  • uploads///GROWTH INDEX EXPO TO IT
    Consumer

    Total Returns and Sector Exposure for Growth Indexes

    If we dig into the S&P 500 and the S&P Growth indexes, we can see that they have the highest exposure to information technology (or IT).

    By Amanda Lawrence
  • uploads///Graph
    Company & Industry Overviews

    Here’s What Drove Supernus Pharmaceuticals Stock in March 2018

    Supernus Pharmaceuticals (SUPN) stock has risen 18.2%, from $38.75 on March 1, 2018, to $45.80 on March 29, 2018.

    By Margaret Patrick
  • uploads///chart
    Macroeconomic Analysis

    A Comparative Analysis of PTH and DWAQ

    PTH and DWAQ have followed similar trends in 2015. PTH has a higher beta than DWAQ because it’s a pure sectoral equity fund, and its trend movement is more significant than DWAQ’s.

    By Ivan Kading
  • uploads///chart
    Macroeconomic Analysis

    An Overview of PTH’s Pharmaceutical and Biotechnology Holdings

    PTH is majorly invested in pharmaceutical companies, with 43.2% of its funds invested in pharmaceutical stocks. The biotechnology subsector comes next with a total share of 28.3%.

    By Ivan Kading
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    On a Bullish Day, IBB Outperformed XLV

    The iShares Nasdaq Biotechnology ETF (IBB) rose 4.4%, the Health Care Select Sector SPDR ETF (XLV) rose 2.2%, and the SPDR S&P 500 ETF (SPY) moved up by 1.5% on October 15.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.